<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383123</url>
  </required_header>
  <id_info>
    <org_study_id>104858</org_study_id>
    <nct_id>NCT00383123</nct_id>
  </id_info>
  <brief_title>Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children</brief_title>
  <official_title>A Phase III, Single-blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix® (GSK Biologicals') Compared With Fluzone® (Aventis Pasteur/Sanofi) Administered Intramuscularly in Children (6 Months and Older)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two influenza vaccines (Fluzone and Fluarix) in terms
      of the immune response elicited and safety with a six month follow-up after first
      vaccination. The Protocol Posting has been updated in order to comply with the FDA Amendment
      Act, Sep 2007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Serum Haemagglutination-inhibition (HI) Antibodies</measure>
    <time_frame>21 or 28 days after last vaccine dose</time_frame>
    <description>GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects</measure>
    <time_frame>21 or 28 days after last vaccine dose</time_frame>
    <description>Seroconverted subjects are defined as subjects with either a pre-vaccination HI titer &lt;1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer.
Data are presented for all 3 viral strains comprised in the vaccine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Rare Serious Events</measure>
    <time_frame>Up to 6 months after vaccination</time_frame>
    <description>Rare serious event is defined as any untoward medical event with an occurrence rate of ≥1/300 that:
resulted in death,
was life-threatening,
required hospitalization or prolongation of existing hospitalization,
resulted in disability/incapacity, or
was a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects</measure>
    <time_frame>Before (PRE) and 21 or 28 days after (POST) the last vaccine dose</time_frame>
    <description>Seroprotected subjects are defined as vaccinees with a serum HI titer ≥ 1:40. Data are presented for all 3 viral strains comprised in the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Initially Unprotected Subjects With at Least a 4 Fold Increase in HI Titer</measure>
    <time_frame>21 or 28 days after last vaccine dose</time_frame>
    <description>Initially unprotected subjects are subjects with a baseline HI titer &lt; 1:40. Data are presented for all 3 viral strains comprised in the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and General Symptoms</measure>
    <time_frame>During a 4-day follow-up period after each vaccination</time_frame>
    <description>Solicited local symptoms assessed include pain, redness, and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, loss of appetite, arthralgia, fatigue, headache, muscle aches, and shivering.
Data across doses are presented. Any = at least one symptom irrespective of intensity/relationship to vaccination; Grade 3: symptom that prevented normal everyday activities; Related: considered by the investigator as related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events</measure>
    <time_frame>Within 28 days following vaccination</time_frame>
    <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Any = at least one symptom irrespective of intensity and relationship to vaccination; Grade 3 = preventing normal activity; Related = considered by the investigator to be causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting New Onset Chronic Illnesses and/or Serious Adverse Events (SAE)</measure>
    <time_frame>Up to 6 months after vaccination</time_frame>
    <description>SAE: any untoward medical occurrence that
resulted in death,
was life-threatening,
required hospitalization or prolongation of existing hospitalization,
resulted in disability/incapacity, or
was a congenital anomaly/birth defect in the offspring of a study subject.
Examples of possible new onset chronic illnesses include but are not limited to diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3327</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Fluarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix™</intervention_name>
    <description>Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children &gt; 12 months of age, in the anterolateral thigh for children &lt; 12 months.
*Only those subjects between the age of 6 months and &lt; 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 &amp; 1.</description>
    <arm_group_label>Fluarix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone</intervention_name>
    <description>Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children &gt; 12 months of age, in the anterolateral thigh for children &lt; 12 months.
*Only those subjects between the age of 6 months and &lt; 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 &amp; 1.</description>
    <arm_group_label>Fluzone Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female child age 6 months to &lt; 18 years at the time of the vaccination;
             children who may or may not have had previous administration of influenza vaccine in a
             previous season are acceptable.

          -  Subjects having a parent/guardian who the investigator believes can and will comply
             with the requirements of the protocol should be enrolled in the study.

          -  Written informed consent obtained from the subject's parent/guardian; assent obtained
             in subjects &gt; 10 years.

          -  Female subjects of childbearing potential must agree to take a pregnancy test.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine, other than the
             study vaccine) within 30 days preceding the administration of the study vaccine, or
             planned use during the study period. Routine, registered childhood vaccinations are
             not an exclusion.

          -  History of hypersensitivity to any vaccine.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine.

          -  Acute disease at the time of enrollment.

          -  History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated
             influenza virus vaccine.

          -  Pregnant or lactating female.

          -  Receipt of an influenza vaccine outside of this study, during current (2006-07) flu
             season.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Antioch</city>
        <state>California</state>
        <zip>94509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fairfield</city>
        <state>California</state>
        <zip>94533</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>California</state>
        <zip>94801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vacaville</city>
        <state>California</state>
        <zip>95688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tifton</city>
        <state>Georgia</state>
        <zip>31794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Whitehouse Station</city>
        <state>New Jersey</state>
        <zip>08889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fishkill</city>
        <state>New York</state>
        <zip>12524</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hopewell Junction</city>
        <state>New York</state>
        <zip>12533</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sylva</city>
        <state>North Carolina</state>
        <zip>28779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2006</study_first_submitted>
  <study_first_submitted_qc>September 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2006</study_first_posted>
  <results_first_submitted>October 15, 2008</results_first_submitted>
  <results_first_submitted_qc>December 3, 2008</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2008</results_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fluarix</keyword>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>104858</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104858</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104858</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104858</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104858</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104858</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104858</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two subjects, enrolled in the Fluzone Group, were not vaccinated; therefore, they were not included in the number of subjects included under &quot;STARTED&quot;.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluarix Group</title>
          <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
        </group>
        <group group_id="P2">
          <title>Fluzone Group</title>
          <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2115"/>
                <participants group_id="P2" count="1210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2004"/>
                <participants group_id="P2" count="1124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluarix Group</title>
          <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
        </group>
        <group group_id="B2">
          <title>Fluzone Group</title>
          <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2115"/>
            <count group_id="B2" value="1210"/>
            <count group_id="B3" value="3325"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" spread="4.97"/>
                    <measurement group_id="B2" value="5.5" spread="4.75"/>
                    <measurement group_id="B3" value="6.8" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1038"/>
                    <measurement group_id="B2" value="586"/>
                    <measurement group_id="B3" value="1624"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1077"/>
                    <measurement group_id="B2" value="624"/>
                    <measurement group_id="B3" value="1701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Serum Haemagglutination-inhibition (HI) Antibodies</title>
        <description>GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine.</description>
        <time_frame>21 or 28 days after last vaccine dose</time_frame>
        <population>Per protocol, GMTs were assessed only in part of the According-To-Protocol (ATP) cohort for immunogenicity (children aged 6 months to &lt; 5 years).</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Group</title>
            <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Group</title>
            <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Serum Haemagglutination-inhibition (HI) Antibodies</title>
          <description>GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine.</description>
          <population>Per protocol, GMTs were assessed only in part of the According-To-Protocol (ATP) cohort for immunogenicity (children aged 6 months to &lt; 5 years).</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia [6 to &lt;36 months] (n=206,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="43.3" upper_limit="63.4"/>
                    <measurement group_id="O2" value="101.4" lower_limit="86.9" upper_limit="118.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [6 to &lt;36 months] (n=206,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" lower_limit="62.2" upper_limit="104.1"/>
                    <measurement group_id="O2" value="218.0" lower_limit="185.8" upper_limit="255.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [6 to &lt;36 months] (n=206,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="15.9" upper_limit="25.8"/>
                    <measurement group_id="O2" value="40.6" lower_limit="32.3" upper_limit="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia [3 to &lt; 5 years] (n=220,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.3" lower_limit="108.6" upper_limit="156.4"/>
                    <measurement group_id="O2" value="168.7" lower_limit="138.7" upper_limit="205.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [3 to &lt; 5 years] (n=220,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458.1" lower_limit="365.3" upper_limit="574.3"/>
                    <measurement group_id="O2" value="483.4" lower_limit="396.8" upper_limit="588.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [3 to &lt; 5 years] (n=220,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" lower_limit="42.3" upper_limit="71.1"/>
                    <measurement group_id="O2" value="64.4" lower_limit="49.5" upper_limit="83.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects</title>
        <description>Seroconverted subjects are defined as subjects with either a pre-vaccination HI titer &lt;1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer.
Data are presented for all 3 viral strains comprised in the vaccine.</description>
        <time_frame>21 or 28 days after last vaccine dose</time_frame>
        <population>As per protocol, seroconversion was assessed in part of the ATP cohort for immunogenicity: children aged 6 months to &lt; 5 years for whom post-vaccination results were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Group</title>
            <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Group</title>
            <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects</title>
          <description>Seroconverted subjects are defined as subjects with either a pre-vaccination HI titer &lt;1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer.
Data are presented for all 3 viral strains comprised in the vaccine.</description>
          <population>As per protocol, seroconversion was assessed in part of the ATP cohort for immunogenicity: children aged 6 months to &lt; 5 years for whom post-vaccination results were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia [6 to &lt;36 months] (n=205,223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [6 to &lt;36 months] (n=205,223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [6 to &lt;36 months] (n=205,223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia [3 to &lt;5 years] (n=220,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [3 to &lt;5 years] (n=220,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [3 to &lt;5 years] (n=220,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Rare Serious Events</title>
        <description>Rare serious event is defined as any untoward medical event with an occurrence rate of ≥1/300 that:
resulted in death,
was life-threatening,
required hospitalization or prolongation of existing hospitalization,
resulted in disability/incapacity, or
was a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Up to 6 months after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Group</title>
            <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Group</title>
            <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Rare Serious Events</title>
          <description>Rare serious event is defined as any untoward medical event with an occurrence rate of ≥1/300 that:
resulted in death,
was life-threatening,
required hospitalization or prolongation of existing hospitalization,
resulted in disability/incapacity, or
was a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2115"/>
                <count group_id="O2" value="1210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects</title>
        <description>Seroprotected subjects are defined as vaccinees with a serum HI titer ≥ 1:40. Data are presented for all 3 viral strains comprised in the vaccine.</description>
        <time_frame>Before (PRE) and 21 or 28 days after (POST) the last vaccine dose</time_frame>
        <population>As per protocol, seroprotection was assessed in part of the ATP cohort for immunogenicity: children aged 6 months to &lt; 5 years for whom results were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Group</title>
            <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Group</title>
            <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects</title>
          <description>Seroprotected subjects are defined as vaccinees with a serum HI titer ≥ 1:40. Data are presented for all 3 viral strains comprised in the vaccine.</description>
          <population>As per protocol, seroprotection was assessed in part of the ATP cohort for immunogenicity: children aged 6 months to &lt; 5 years for whom results were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia [6 to &lt;36 months] PRE (n=205,223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia [6 to &lt;36 months] POST (n=206,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [6 to &lt;36 months] PRE (n=205,223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [6 to &lt;36 months] POST (n=206,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [6 to &lt;36 months] PRE (n=205,223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [6 to &lt;36 months] POST (n=206,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia [3 to &lt;5 years] PRE (n=220,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia [3 to &lt;5 years] POST (n=220,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [3 to &lt;5 years] PRE (n=220,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [3 to &lt;5 years] POST (n=220,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O2" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [3 to &lt;5 years] PRE (n=220,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [3 to &lt;5 years] POST (n=220,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Initially Unprotected Subjects With at Least a 4 Fold Increase in HI Titer</title>
        <description>Initially unprotected subjects are subjects with a baseline HI titer &lt; 1:40. Data are presented for all 3 viral strains comprised in the vaccine.</description>
        <time_frame>21 or 28 days after last vaccine dose</time_frame>
        <population>As per protocol, only subjects from the ATP cohort for immunogenicity aged 6 months to &lt; 5 years and with a baseline titre &lt; 1:40 were analysed for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Group</title>
            <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Group</title>
            <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Initially Unprotected Subjects With at Least a 4 Fold Increase in HI Titer</title>
          <description>Initially unprotected subjects are subjects with a baseline HI titer &lt; 1:40. Data are presented for all 3 viral strains comprised in the vaccine.</description>
          <population>As per protocol, only subjects from the ATP cohort for immunogenicity aged 6 months to &lt; 5 years and with a baseline titre &lt; 1:40 were analysed for this Outcome Measure.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="405"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia [6 to &lt;36 months] (n=190, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [6 to &lt;36 months] (n=166,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [6 to &lt;36 months] (n=194,211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia [3 to &lt;5 years] (n=182,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [3 to &lt;5 years] (n=89,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [3 to &lt;5 years] (n=190,194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness, and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, loss of appetite, arthralgia, fatigue, headache, muscle aches, and shivering.
Data across doses are presented. Any = at least one symptom irrespective of intensity/relationship to vaccination; Grade 3: symptom that prevented normal everyday activities; Related: considered by the investigator as related to the study vaccination.</description>
        <time_frame>During a 4-day follow-up period after each vaccination</time_frame>
        <population>Analysis was performed on vaccinated subjects with available data.
Pain, redness, swelling and fever were assessed in all age cohorts.
Drowsiness, irritability and loss of appetite were assessed in the 6 months to &lt; 5 years cohort only.
Arthralgia, fatigue, headache, muscle aches and shivering were assessed in the 5 to &lt; 18 years cohort only.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Group</title>
            <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Group</title>
            <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness, and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, loss of appetite, arthralgia, fatigue, headache, muscle aches, and shivering.
Data across doses are presented. Any = at least one symptom irrespective of intensity/relationship to vaccination; Grade 3: symptom that prevented normal everyday activities; Related: considered by the investigator as related to the study vaccination.</description>
          <population>Analysis was performed on vaccinated subjects with available data.
Pain, redness, swelling and fever were assessed in all age cohorts.
Drowsiness, irritability and loss of appetite were assessed in the 6 months to &lt; 5 years cohort only.
Arthralgia, fatigue, headache, muscle aches and shivering were assessed in the 5 to &lt; 18 years cohort only.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2039"/>
                <count group_id="O2" value="1149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain [Any] (n=2039,1149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1072"/>
                    <measurement group_id="O2" value="526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain [Grade 3] (n=2039,1149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness [Any] (n=2039,1149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421"/>
                    <measurement group_id="O2" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness [&gt; 50 mm] (n=2039,1149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling [Any] (n=2039,1149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling [&gt; 50 mm] (n=2039,1149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness [Any] (n=691,697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness [Grade 3] (n=691,697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness [Related] (n=691,697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever [≥37.5°C] (n=2039,1148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever [&gt; 39°C] (n=2039,1148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever [Related] (n=2039,1148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability [Any] (n=691,697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability [Grade 3] (n=691,697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability [Related] (n=691,697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite [Any] (n=691,697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite [Grade 3] (n=691,697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite [Related] (n=691,697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia [Any] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia [Grade 3] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia [Related] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue [Any] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue [Grade 3] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue [Related] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache [Any] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache [Grade 3] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache [Related] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches [Any] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches [Grade 3] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches [Related] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering [Any] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering [Grade 3] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering [Related] (n=1348,451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
        <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Any = at least one symptom irrespective of intensity and relationship to vaccination; Grade 3 = preventing normal activity; Related = considered by the investigator to be causally related to the study vaccination.</description>
        <time_frame>Within 28 days following vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Group</title>
            <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Group</title>
            <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
          <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Any = at least one symptom irrespective of intensity and relationship to vaccination; Grade 3 = preventing normal activity; Related = considered by the investigator to be causally related to the study vaccination.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2115"/>
                <count group_id="O2" value="1210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="700"/>
                    <measurement group_id="O2" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting New Onset Chronic Illnesses and/or Serious Adverse Events (SAE)</title>
        <description>SAE: any untoward medical occurrence that
resulted in death,
was life-threatening,
required hospitalization or prolongation of existing hospitalization,
resulted in disability/incapacity, or
was a congenital anomaly/birth defect in the offspring of a study subject.
Examples of possible new onset chronic illnesses include but are not limited to diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders.</description>
        <time_frame>Up to 6 months after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Group</title>
            <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Group</title>
            <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting New Onset Chronic Illnesses and/or Serious Adverse Events (SAE)</title>
          <description>SAE: any untoward medical occurrence that
resulted in death,
was life-threatening,
required hospitalization or prolongation of existing hospitalization,
resulted in disability/incapacity, or
was a congenital anomaly/birth defect in the offspring of a study subject.
Examples of possible new onset chronic illnesses include but are not limited to diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2115"/>
                <count group_id="O2" value="1210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New onset chronic illnesses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluarix Group</title>
          <description>Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
        </group>
        <group group_id="E2">
          <title>Fluzone Group</title>
          <description>Subjects in this group received Fluzone and will be further stratified by 3 age groups
1:1 in 6 months to &lt; 36 months
1:1 in 3 to &lt; 5 years
3:1 in 5 to &lt; 18 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11"/>
                <counts group_id="E2" subjects_affected="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Meningitis enteroviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1072"/>
                <counts group_id="E2" subjects_affected="526"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="1210"/>
              </event>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="1072" subjects_at_risk="2039"/>
                <counts group_id="E2" subjects_affected="526" subjects_at_risk="1149"/>
              </event>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="421" subjects_at_risk="2039"/>
                <counts group_id="E2" subjects_affected="233" subjects_at_risk="1149"/>
              </event>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="308" subjects_at_risk="2039"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="1149"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="691"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Axillary fever</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="2039"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="1148"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="691"/>
                <counts group_id="E2" subjects_affected="246" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="691"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="1348"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="285" subjects_at_risk="1348"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="1348"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="410" subjects_at_risk="1348"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="1210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="2115"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="1210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

